Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 11 - 20 of about 123   

Articles published

GSK 1,451.53 -5.47 (-0.38%)
price chart
Welch & Forbes LLC Increased Glaxosmithkline Plc (NYSE:GSK) by $6.90 Million ...
Welch & Forbes Llc increased its stake in Glaxosmithkline Plc (NYSE:GSK) by 34.66% based on its latest 2016Q1 regulatory filing with the SEC.
Should you sell GlaxoSmithKline plc for this reason?
That's why GlaxoSmithKline (LSE: GSK) CEO Sir Andrew Witty's planned retirement from the business in March 2017 is a factor that needs to be taken into account before buying a slice of the healthcare major.
Why you should -- and shouldn't -- pile into GlaxoSmithKline plc  AOL Money UK
Two Buzzers within Analysts Radar: Baxter International Inc. (NYSE:BAX ...  Street Updates
Is BTG plc a better buy than GlaxoSmithKline plc?
British investing great Neil Woodford has said several times that the pharmaceutical industry is one of Britain's great strengths, and is worthy of investing in.
Analyst's Report Recap: GlaxoSmithKline plc (ADR) (NYSE:GSK)
The mean price target for the shares of GlaxoSmithKline plc (ADR) (NYSE:GSK)is at $47.00 while the highest price target suggested by the analysts is $49.00 and low price target is $44.00.
Cowen and Company Lowers GlaxoSmithKline plc (GSK) to Market Perform  The Cerbat Gem
Key Stocks of the Day: GlaxoSmithKline plc (NYSE:GSK)  The News Journal
Is now the perfect time to buy AstraZeneca plc & GlaxoSmithKline plc?
Have you been keeping an eye on the FTSE 100's big pharmaceuticals companies? I have, and though it might not have been the most exciting of spectator sports, they've been edging ever closer to a return to earnings growth.
Why GlaxoSmithKline plc, Allergy Therapeutics plc and Consort Medical plc are ...
One notable business within the healthcare sector is GlaxoSmithKline (LSE: GSK). It offers a large amount of diversity through having three segments to its business, with pharmaceuticals, vaccines and consumer goods combining to create a relatively low ...
The numbers don't lie, GlaxoSmithKline plc is set to beat AstraZeneca plc this ...
GlaxoSmithKline (LSE: GSK) has made a great start to 2016. The company's first-quarter results released at the end of last week, showed that Glaxo is on course to increase earnings by 10% to 12% this year, which is slightly ahead of market expectations.
Have GlaxoSmithKline plc, Diageo plc and WM Morrison plc finally turned the ...
Pharmaceutical giant GlaxoSmithKline (LSE: GSK) is seen as one of the safest bets on the FTSE 100 but it has hasn't been a winning one in recent years.
Novartis AG (NYSE:NVS) Ultibro Is Performing Better Than GlaxoSmithKline plc ...
The New England Journal of Medicine published data revealing that the Novartis AG (NYSE:NVS)'s Ultibro Breezhaler is doing better than the GlaxoSmithKline plc (NYSE:GSK)'s Seretide. Seretide also is known as Advair in the United States, and prevents ...
GlaxoSmithKline plc's lead over AstraZeneca plc hits 20% and there's more to come
The pharmaceutical sector is one of the most defensive sectors around, and I think investors should always have some exposure to this essential industry in their portfolio.